Increasing adoption of prostate MRI and genomic testing may reduce overtreatment of prostate cancer, according to investigators.
The median rPFS was 24.0 months in the apalutamide arm and 16.6 months in the placebo arm.
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
In a study of men with prostate cancer or a family history of the disease, a higher proportion of men opted to view an educational video over personal genetic counseling prior to genetic testing.
The proteins were only predictive for African-American patients, not European-American patients.
A retrospective study of Medicare data showed a potential factor in nonadherence to oral cancer treatment regimens.
68Ga-PSMA-11 PET scans have a 40% sensitivity for detecting pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer, data show.
In a large retrospective study, radical prostatectomy was significantly associated with a survival advantage among men with high-risk prostate cancer compared with external beam radiation therapy.
The 3-year prostate cancer-specific survival decreased significantly for insured patients.
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
Patients with basal tumors did not derive a significant survival benefit from androgen signaling inhibitors.
The nonrandomized, multicenter, multicohort, open-label, phase 1b/2 KEYNOTE-365 trial evaluated the safety, tolerability, and efficacy of pembrolizumab combination therapy in men with mCRPC.
CRFS after relugolix was not significantly different compared with leuprolide in men with advanced prostate cancer and metastatic disease.
ADT exposure after prostate cancer treatment is associated with the onset of dementia.
RT for prostate cancer is associated with distinct treatment-related complications such as cystitis and urinary stricture.
Treatment discontinuation from adverse events in real-world use is 32% higher for apalutamide and 49% higher for enzalutamide than reported in clinical trials of patients with non-metastatic castration-resistant prostate cancer.
Using abiraterone plus prednisolone with standard androgen deprivation therapy should be considered a new standard of care for patients with high-risk nonmetastatic prostate cancer, according to investigators.
The risk was most elevated for those to arrive earliest at the site.
Enzalutamide plus androgen deprivation therapy improved overall survival by 34%.
The decrease in prostate cancer screening rates was the smallest among 5 cancers studied.